Providence Capital Advisors’s Amgen AMGN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q4
Sell
-3
Closed -$967 129
2024
Q3
$967 Sell
3
-45
-94% -$14.7K ﹤0.01% 328
2024
Q2
$15K Buy
48
+3
+7% +$881 ﹤0.01% 218
2024
Q1
$12.8K Sell
45
-100
-69% -$29.3K ﹤0.01% 232
2023
Q4
$41.8K Buy
145
+34
+31% +$9.26K 0.01% 175
2023
Q3
$29.8K Buy
+111
New +$27.7K 0.01% 185
2022
Q4
Sell
-25
Closed -$6K 298
2022
Q3
$6K Hold
25
﹤0.01% 233
2022
Q2
$6K Sell
25
-102
-80% -$25K ﹤0.01% 226
2022
Q1
$31K Sell
127
-101
-44% -$23.2K 0.01% 199
2021
Q4
$51K Sell
228
-154
-40% -$32.5K 0.01% 154
2021
Q3
$81K Buy
+382
New +$87.9K 0.03% 136
2021
Q1
Sell
-66
Closed -$15K 280
2020
Q4
$15K Buy
+66
New +$15.2K 0.01% 196
2020
Q2
Sell
-229
Closed -$47K 188
2020
Q1
$47K Buy
+229
New +$50K 0.03% 115
2019
Q3
Sell
-3
Closed -$1K 221
2019
Q2
$1K Buy
+3
New +$537 ﹤0.01% 227

Other funds holding AMGN

Providence Capital Advisors's AMGN Position: Q4 2024 in Review

Providence Capital Advisors sold out of Amgen (AMGN) in Q4 2024, closing a stake of 3 shares — an estimated $967 sold.

Providence Capital Advisors first reported a position in AMGN in Q2 2019 and held it in 13 quarters. The position peaked at $81K in Q3 2021. 2,855 funds tracked by Wall St. Rank hold AMGN as of Q4 2024.

  • Providence Capital Advisors reported no remaining Amgen position as of Q4 2024 after selling out during the quarter.
  • Providence Capital Advisors sold 3 Amgen shares in Q4 2024, an estimated $967.
  • Providence Capital Advisors first reported a position in Amgen in Q2 2019 and held it in 13 quarters.
  • Providence Capital Advisors's Amgen position peaked at $81K in Q3 2021.
  • 2,855 funds tracked by Wall St. Rank held Amgen as of Q4 2024.

Based on Providence Capital Advisors's 13F filing for Q4 2024, filed 12 Feb 2025.